Endemic Burkitt lymphoma is associated with strength and diversity of Plasmodium falciparum malaria stage-specific antigen antibody response

Blood

Volumn 122, Issue 5, 2013, Pages 629-635

  Aka, Peter ^a   Vila, Maria Candida ^b   Jariwala, Amar ^b   Nkrumah, Francis ^c   Emmanuel, Benjamin ^a   Yagi, Masanori ^d   Palacpac, Nirianne Marie Q ^d   Periago, Maria V ^b   Neequaye, Janet ^e   Kiruthu, Christine ^a   Tougan, Takahiro ^d   Levine, Paul H ^b   Biggar, Robert J ^f   Pfeiffer, Ruth M ^a   Bhatia, Kishor ^a   Horii, Toshihiro ^d   Bethony, Jeffrey M ^b   Mbulaiteye, Sam M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c University of Ghana   (Ghana)

^d OSAKA UNIVERSITY   (Japan)

^e Department of Child Health   (Ghana)

^f QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

6 TETRAPEPTIDE; CIRCUMSPOROZOITE PROTEIN; HISTIDINE RICH PROTEIN II; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; SE36 ANTIGEN; TETANUS TOXOID; TETRAPEPTIDE; UNCLASSIFIED DRUG; PARASITE ANTIGEN;

ADOLESCENT; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ARTICLE; BURKITT LYMPHOMA; CHILD; CONFIDENCE INTERVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GHANA; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; NEWBORN; PRIORITY JOURNAL; ANIMAL; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; CASE CONTROL STUDY; ENDEMIC DISEASE; GENETIC VARIABILITY; GENETICS; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; LIFE CYCLE STAGE; PARASITOLOGY; PHYSIOLOGY; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD;

ADOLESCENT; ANIMALS; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; ANTIGENS, PROTOZOAN; BURKITT LYMPHOMA; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; ENDEMIC DISEASES; FEMALE; GENETIC VARIATION; HUMANS; INFANT; INFANT, NEWBORN; LIFE CYCLE STAGES; MALARIA, FALCIPARUM; MALE; PLASMODIUM FALCIPARUM;

EID: 84886425494     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-12-475665     Document Type: Article

References (38)

1. Parkin DM, Sitas F, Chirenje M, Stein L, Abratt R, Wabinga H. Part I: Cancer in Indigenous Africans—burden, distribution, and trends. Lancet Oncol. 2008;9(7):683-692.
2. Burkitt DP. Etiology of Burkitt’s lymphoma—an alternative hypothesis to a vectored virus. J Natl Cancer Inst. 1969;42(1):19-28.
3. Morrow RH Jr. Epidemiological evidence for the role of falciparum malaria in the pathogenesis of Burkitt’s lymphoma. IARC Sci Publ. 1985;(60): 177-186.
4. Klein G. Burkitt lymphoma—a stalking horse for cancer research? Semin Cancer Biol. 2009;19(6): 347-350.
5. Rochford R, Cannon MJ, Moormann AM. Endemic Burkitt’s lymphoma: a polymicrobial disease? Nat Rev Microbiol. 2005;3(2):182-187.
6. Proceedings of the IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Epstein-Barr virus and Kaposi’s sarcoma herpesvirus/human herpesvirus 8. Lyon, France, 17-24 June 1997. IARC Monogr Eval Carcinog Risks Hum. 1997;70:1-492.
7. Bouvard V, Baan RA, Grosse Y, et al; WHO International Agency for Research on Cancer Monograph Working Group. Carcinogenicity of malaria and of some polyomaviruses. Lancet Oncol. 2012;13(4):339-340.
8. Ziegler JL, Bluming AZ, Morrow RH Jr, Cohen MH, Fife EH Jr, Finerty JF, Woods R. Burkitt’s lymphoma and malaria. Trans R Soc Trop Med Hyg. 1972;66(2):285-291.
9. Feorino PM, Mathews HM. Malaria antibody levels in patients with Burkitt’s lymphoma. Am J Trop Med Hyg. 1974;23(4):574-576.
10. Mutalima N, Molyneux E, Jaffe H, et al. Associations between Burkitt lymphoma among children in Malawi and infection with HIV, EBV and malaria: results from a case-control study. PLoS ONE. 2008;3(6):e2505.
11. Carpenter LM, Newton R, Casabonne D, et al. Antibodies against malaria and Epstein-Barr virus in childhood Burkitt lymphoma: a case-control study in Uganda. Int J Cancer. 2008;122(6): 1319-1323.
12. Langhorne J, Ndungu FM, Sponaas AM, Marsh K. Immunity to malaria: more questions than answers. Nat Immunol. 2008;9(7):725-732.
13. Barry AE, Trieu A, Fowkes FJ, et al. The stability and complexity of antibody responses to the major surface antigen of Plasmodium falciparum are associated with age in a malaria endemic area. Mol Cell Proteomics. 2011;10(11): M111.008326.
14. Crompton PD, Kayala MA, Traore B, et al. A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proc Natl Acad Sci USA. 2010;107(15):6958-6963.
15. Kinyanjui SM, Bejon P, Osier FH, Bull PC, Marsh K. What you see is not what you get: implications of the brevity of antibody responses to malaria antigens and transmission heterogeneity in longitudinal studies of malaria immunity. Malar J. 2009;8:242.
16. Hill AV. Vaccines against malaria. Philos Trans R Soc Lond B Biol Sci. 2011;366(1579):2806-2814.
17. Guech-Ongey M, Yagi M, Palacpac NM, et al. Antibodies reactive to Plasmodium falciparum serine repeat antigen in children with Burkitt lymphoma from Ghana. Int J Cancer. 2012; 130(8):1908-1914.
18. Palacpac NM, Arisue N, Tougan T, Ishii KJ, Horii T. Plasmodium falciparum serine repeat antigen 5 (SE36) as a malaria vaccine candidate. Vaccine. 2011;29(35):5837-5845.
19. Okech B, Mujuzi G, Ogwal A, Shirai H, Horii T, Egwang TG. High titers of IgG antibodies against Plasmodium falciparum serine repeat antigen 5 (SERA5) are associated with protection against severe malaria in Ugandan children. Am J Trop Med Hyg. 2006;74(2):191-197.
20. Ogutu BR, Apollo OJ, McKinney D, et al; MSP-1 Malaria Vaccine Working Group. Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS ONE. 2009;4(3):e4708.
21. Hopkins H, Kambale W, Kamya MR, Staedke SG, Dorsey G, Rosenthal PJ. Comparison of HRP2- and pLDH-based rapid diagnostic tests for malaria with longitudinal follow-up in Kampala, Uganda. Am J Trop Med Hyg. 2007;76(6):1092-1097.
22. Nothdurft HD, Jelinek T, Blüml A, von Sonnenburg F, Löscher T. Seroconversion to circumsporozoite antigen of Plasmodium falciparum demonstrates a high risk of malaria transmission in travelers to East Africa. Clin Infect Dis. 1999;28(3):641-642.
23. Nkrumah FK, Olweny CL. Clinical features of Burkitt’s lymphoma: the African experience. IARC Sci Publ. 1985;(60):87-95.
24. Nkrumah FK, Sulzer AJ, Maddison SE. Serum immunoglobulin levels and malaria antibodies in Burkitt’s lymphoma. Trans R Soc Trop Med Hyg. 1979;73(1):91-95.
25. Gardiner C, Biggar RJ, Collins WE, Nkrumah FK. Malaria in urban and rural areas of southern Ghana: a survey of parasitaemia, antibodies, and antimalarial practices. Bull World Health Organ. 1984;62(4):607-613.
26. Nkrumah FK, Perkins IV. Sickle cell trait, hemoglobin C trait, and Burkitt’s lymphoma. Am J Trop Med Hyg. 1976;25(4):633-636.
27. Sauerwein RW, Roestenberg M, Moorthy VS. Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol. 2011;11(1): 57-64.
28. Miura K, Orcutt AC, Muratova OV, Miller LH, Saul A, Long CA. Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines. Vaccine. 2008; 26(2):193-200.
29. Lam KM, Syed N, Whittle H, Crawford DH. Circulating Epstein-Barr virus-carrying B cells in acute malaria. Lancet. 1991;337(8746):876-878.
30. Chene A, Donati D, Orem J, Mbidde ER, Kironde F, Wahlgren M, Bejarano MT. Endemic Burkitt’s lymphoma as a polymicrobial disease: new insights on the interaction between Plasmodium falciparum and Epstein-Barr virus. Semin Cancer Biol. 2009;19(6):411-420.
31. McFarlane H, Barrow RO, Ngu VA, Osunkoya BO. Excretion of immunoglobulins in Burkitt’s lymphoma. Br J Cancer. 1970;24(2):258-259.
32. Morrow H, Pike MC, Smith P, Ziegler JL. Preliminary epidemiological findings of Burkitt’s lymphoma in the Mengo Districts, Uganda, 1959-1968. Cancer Res. 1974;34(5): 1211-1212.
33. Ngu VA. Host defences to Burkitt tumour. BMJ. 1967;1(5536):345-347.
34. Asito AS, Piriou E, Odada PS, et al. Elevated anti-Zta IgG levels and EBV viral load are associated with site of tumor presentation in endemic Burkitt’s lymphoma patients: a case control study. Infect Agent Cancer. 2010;5:13.
35. Agnandji ST, Lell B, Soulanoudjingar SS, et al; RTS,S Clinical Trials Partnership. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med. 2011;365(20): 1863-1875.
36. Schulz KF, Grimes DA. Case-control studies: research in reverse. Lancet. 2002;359(9304): 431-434.
37. Grimes DA, Schulz KF. Compared to what? Finding controls for case-control studies. Lancet. 2005;365(9468):1429-1433.
38. Gislefoss RE, Grimsrud TK, Mørkrid L. Stability of selected serum proteins after long-term storage in the Janus Serum Bank. Clin Chem Lab Med. 2009;47(5):596-603.